Low molecular weight heparin treatment of venous thromboembolism
- 1 September 1994
- journal article
- review article
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 37 (2) , 71-78
- https://doi.org/10.1016/s0033-0620(05)80043-x
Abstract
No abstract availableFunding Information
- Heart and Stroke Foundation of Canada
- Novo Nordisk
This publication has 52 references indexed in Scilit:
- Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight HeparinsDrugs, 1990
- Heparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous ThrombosisNew England Journal of Medicine, 1990
- The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mgThe Journal of Clinical Pharmacology, 1988
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1986
- Low-Molecular-Weight HeparinNew England Journal of Medicine, 1986
- The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge.Circulation, 1983
- Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1982
- Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous ThrombosisNew England Journal of Medicine, 1982
- Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous ThrombosisNew England Journal of Medicine, 1979
- Combined Use of Leg Scanning and Impedance Plethysmography in Suspected Venous ThrombosisNew England Journal of Medicine, 1977